The creatinine correction approach has been used to estimate daily intake for contaminants whose primary route of elimination is through urine. This method is challenged using the phthalate di-2-ethylhexyl phthalate (DEHP) as an example. An alternate prediction approach based on human experimental metabolism and urinary excretion data on DEHP was developed. This alternate model was developed from urine measurements of four metabolites of DEHP from two individuals partaking in different experiments, for up to 44 h after known exposures. Particular attention was paid to the changing ratios of the metabolites over time: they took a certain form when exposure was in the ''near'' (the past few hours) versus the ''distant'' (24 h or more) past. The creatinine correction approach was applied to measurements of the same four metabolites from 18 individuals in the National Health And Nutrition Evaluation Survey (NHANES) 2003/2004. The alternate model was also applied to these individuals, and the results were compared. Predictions using the two methods were similar or the creatinine correction predicted higher concentrations when the ratio suggested that the DEHP exposure was ''near'' in time, but the alternate approach predicted intakes that were an order of magnitude higher when the ratios suggested that the intake was ''distant''. As much as 25% of all NHANES measurements contain metabolites whose key ratio suggest that exposure was ''distant''. Uncertainties notwithstanding, the analysis in this article suggests that the creatinine correction approach should be used cautiously for DEHP and possibly other contaminants with similar exposure characteristics: rapid metabolism with metabolite urine elimination half-lives on the order of hours, and exposure patterns that may not be continuous and ongoing.
Introduction
Creatinine is excreted from muscles and eliminated through urination on an ongoing basis. Equations relating an individual's age, sex, and race to total daily elimination of creatinine have been developed (Cockcroft and Gault, 1976; Mage et al., 2004 Mage et al., , 2008 . Therefore, the amount of creatinine in a spot urine sample can be related back to a full daily excretion of creatinine. If exposure to a contaminant is continuous, perhaps on a daily basis if not frequently within a day and the primary means of elimination of that contaminant is through urine, the creatinine correction approach can be used to estimate daily intake of that contaminant. The premise is that, assuming steady state exposure and urinary excretion, daily intakes equal daily urinary eliminations. A ratio of a spot sample excretion of creatinine and total daily excretion of creatinine should equal the ratio of the spot sample excretion of the contaminant and the total daily excretion of the contaminant. The purpose of this study was to question this premise, as applied to the phthalate, di-2-ethylhexyl phthalate (DEHP).
The creatinine correction approach has been used to estimate intakes of a variety of contaminants. Biomonitoring programs, such as the National Health and Nutrition Evaluation Survey (NHANES) or the German Environmental Surveys regularly measure creatinine in a urine sample along with other target constituents. It has been used for a variety of pesticides (Fenske et al., 2000; Mage et al., 2004) and conservative (i.e., those that don not, or mostly don not metabolize) contaminants such as perchlorate (Blount et al., 2007) . In the case of contaminants that metabolize, such as phthalates or pesticides, it is most often not the parent compound that is measured but rather the metabolites. Numerous researchers have used the approach applied to phthalate metabolites to estimate daily intakes of parent phthalates (David, 2000; Kohn et al., 2000; Marsee et al., 2006) . These researchers base their estimate on the first metabolite produced: the monoester phthalate metabolite. In fact, parent phthalates are not measured in urine. The formation of metabolites of phthalates is so rapid that the parent phthalate is not expected to appear in urine, and a second justification given is that both sampling and laboratory equipment may be contaminated with the parent phthalate. For DEHP, the first metabolite is mono-(2-ethylhexyl) phthalate (MEHP), and it is this metabolite that has been most often related to daily intakes using the creatinine correction approach.
However, the creatinine correction approach is only as valid as the key assumption of steady state intakes. To be more precise, this approach is only as valid as an assumption that excretions are steady over time. Such steadiness would occur if intakes were steady and daily, but excretions might also be reasonably consistent over time if the intakes occurred less frequently, say once every 3 days, but the elimination in urine was very slow, say with half-lives on the order of days. In reality, and as discussed below in more detail, DEHP metabolites are eliminated with half-lives on the order of hours, not days. MEHP, for example, has a half-life that has been measured at 5 h. Given this fact, one does not know if a concentration of MEHP in urine resulted from an exposure in the recent few hours, or if it was the result of a very high exposure the previous day or two. Very little is known about the day-to-day or within-day patterns of DEHP intake. Wormuth et al. (2006) provide one of the few comprehensive evaluations of intakes of phthalates based on model calculations. Their approach is a ''forward'' approach to estimating intakes. That is, they model intake of phthalates through consumption of food, intake from consumer products, inhalation, and dust/soil exposures based on parent phthalate concentrations in these exposure media in combination with contact rates. Their analysis encompasses several phthalates for Europeans of several age ranges. They found that exposures were highest for DEHP, at between 1 and 5 mg/kg/day for children, teens, and adults. Exposures were always higher for infants, getting above 10 mg/kg/day for DEHP. Ingestion of food dominated for DEHP. There was much variability (the range from minimal to maximal exposures within consumer groups was about a factor of 100) and uncertainty in this exercise, based primarily on the paucity of data on phthalates in food or consumer products. Franco et al. (2007) conducted a quantitative assessment using two forward modeling approaches focusing on individual pathways of exposure, similar to that conducted by Wormuth et al. (2006) . By one method, they arrived at a median total daily intake of 5.6 mg/kg/day for DEHP, but by the other method, they arrived at much lower median intake of 0.68 mg/kg/day.
One key aspect of both forward and backward approaches is that they assume average, steady state behaviors. Average behaviors are, in reality, a mix of typical behaviors, as well as extremes at both ends. An average daily consumption rate of a food, for example, could very easily arise from a meal of that food one day and then no consumption for several days. If phthalates are associated with the food, then this exposure could result in elevated concentrations of metabolites in the urine for several hours after the exposure, but much smaller to trace concentrations in the days following. The potential issue with use of the creatinine correction approach is now apparent F a low concentration could mistakenly imply a low daily intake when in reality a large intake may have caused the low concentration.
The problem becomes more exaggerated as the rate of elimination increases F when elimination occurs much more rapidly. The elimination half-life of MEHP has been reported as 5 h in a human metabolism experiment (Koch et al., 2005b) , so that 24 h after exposure, five halflives have passed, and only about 3% of the total mass of MEHP that was formed by the exposure remains to be eliminated. It is easy to see that a day following an exposure to DEHP, the concentration of MEHP could be very low or fall below a detection limit. Meanwhile, secondary metabolites could be still forming if their rate of formation and excretion is slower than that of MEHP. Koch et al. (2005b) measured four additional metabolites of DEHP in the experiment, and found that these secondary metabolites of DEHP have elimination half-lives in the range of 10-15 h. This implies that MEHP might be a poor candidate as an indication of exposure to DEHP. Indeed, Barr et al. (2003) advocated the urinary analysis of secondary metabolites of phthalates as perhaps better indicators of exposure, compared with the monoester primary phthalate metabolites, for just this reason. The NHANES program now measures for more than just MEHP, the primary metabolite of DEHP. Starting with NHANES 2001/2002, three secondary and tertiary metabolites of DEHP were measured and four metabolites from NHANES 2003/2004 (MEHP plus three secondary metabolites) were used in this study.
This article explores the possibility that a relationship between a tertiary and a secondary metabolite of DEHP in urine can shed light on the timing and magnitude of exposure to DEHP. Experimental data were obtained from two individuals: one who self-dosed and one whose exposure was through an apheresis blood platelet donation procedure. Both exposures were substantially elevated above background (see discussions below). The exposures were halted and then urine was collected and analyzed for five primary DEHP metabolites for up to 48 h after the exposure. Initial high concentrations of DEHP metabolites in urine declined rapidly over the 24 h following exposure. Urine samples were taken up to 24 h after the apheresis procedure ended and 44 h after the self-dosed exposure. These data show not only declines over time, but also changes in the relationships of metabolites to each other. It is this trend of changing relationships that is exploited in the draft model developed in this study.
The simple model proposed in this study, which is not considered mature enough for general usage, is based on the experimental data from these two individuals. Specifically a concentration ratio between a tertiary and a secondary metabolite is developed. When this ratio is near 1.0, the hypothesis is that exposure was recent, for example within the past few hours. However, when this ratio is greater than 1.0, in the range of 1.5-2.0 and higher, the hypothesis is that exposure occurred several hours earlier, greater than 10 h or even the previous day. Individual measurements of DEHP metabolites in urine are retrieved from the NHANES 2003/ 2004 database. Subsequently, assuming these profiles of DEHP metabolites each arose from a single exposure (and this assumption is explored in the discussion section later), the ratio of the secondary metabolites informs as to whether the exposure was ''near'' in time to the measurement or ''distant'' in time from the measurement. Then, the proposed model (with a differing coefficient based on the ''near'' or ''distant'' judgment) is used to estimate the single dose, which may have produced the measurement. Concurrently, the NHANES measurements, including pertinent demographic data, are used in the creatinine correction model to estimate intakes. The two sets of estimates are compared, and important differences are observed. As inferred from the discussions above, when the exposure was in the ''distant'' past, the creatinine correction approach estimated much less of a daily intake, by factors of 10 or more, as compared with the alternate approach. When the exposure was ''near'', both methods estimated comparable intakes, and in fact, the creatinine correction approach estimated higher intakes in some cases.
Materials and methods
Following an exposure to DEHP, the first metabolite generated is the monoester metabolite, MEHP. Numerous secondary and tertiary metabolites are generated, but four others have been measured in urine: mono-(2-ethyl-5-oxohexyl) phthalate (5oxo-MEHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (5OH-MEHP), mono ((2-carboxymethy)hexyl) phthalate (2cx-MMHP), and mono (2-ethyl-5-carboxypentyl) phthalate, (5cx-MEPP). This study focuses on four of the five metabolites: MEHP, 5oxo-MEHP, 5OH-MEHP, and 5cx-MEPP. The estimated elimination half-lives (in hours) and percentage of total dose that appears in urine after 24 h for the five metabolites are (Koch et al., 2005b) : 5 h and 5.9% for MEHP, 10 h and 23.3% for 5OH-MEHP, 10 h and 15.0% for 5oxo-MEHP, 15 h and 18.5% for 5cx-MEPP, and 424 h and 4.2% for 2xc-MMHP. Excretions of the four metabolites studied in this study explain about 63% of the initial intake of DEHP; 2cx-MMHP (the metabolite not researched here) explains only about 4% of the total intake. The tertiary metabolite, 5cx-MEPP, has the longest half-life, and is the second most dominant metabolite with regard to how much of the initial molar dose it explains. The secondary metabolite, 5OH-MEHP, is the highest at 23.3% with 5cx-MEPP next at 18.5%. What these facts translates to, in practical terms and for purposes in this study, is that while other metabolites are forming and being excreted at a more rapid pace than 5cx-MEPP, it is this tertiary metabolite that eventually dominates the profile of a urine sample of DEHP metabolites. Assuming no other exposure to DEHP occurs, the data below show that, initially after exposure, 5OH-MEHP is the metabolite with the highest concentration. After about 10 h or so, 5cx-MEPP becomes the metabolite with the highest concentration, and remains as such, as the intake of DEHP is being depleted over the 48 h or so after exposure ceases. In other words, initially after exposure, the ratio of 5cx-MEPP to 5OH-MEHP in a spot urine sample is less than 1.0, but after 10 h or so, this ratio exceeds 1.0. The ratio of 5cx-MEPP to 5OH-MEHP in a spot urine sample will be the indicator used below in the model to indicate whether the exposure was in the ''near'' or ''distant'' past.
Experimental data were retrieved for two individuals, including an individual who self-dosed at an amount significantly higher than typical background exposures and an individual whose elevated exposure was due to an apheresis blood platelet donation procedure. The Supplementary Material includes data on three other individuals who fasted. As the data and discussion will show, key trends in these fasting individuals mirror those of these two highly dosed individuals. Following is a summary of the experimental data for the two highly dosed individuals. A listing of the detailed data for these individuals is provided in the Supplementary Material to this article.
Self-dosed Individual
This individual, 61 years old and having 75 kg body weight, self-dosed an amount of 48.5 mg DEHP by consuming a piece of buttered toast into which stable-isotope-labeled DEHP was mixed. Concentrations of five metabolites of DEHP in his urine were measured over the next 44 h. The experiment was described in Koch et al. (2004 Koch et al. ( , 2005b . On a body weight basis, this 48.5 mg translates to 650 mg/kg. This differs from median intakes determined from urine measurements and the creatinine correction approach that ranges from about 1 mg/kg/day in the United States (Lorber et al., 2010) to 5 mg/kg/day based on urine measurements from German study participants (Wittassek et al., 2007b) . As observed, this dose is clearly elevated above background and this is observed also in the urine concentration data. For example, concentrations of MEHP in the first several samples from this individual (through about 10 h) ranged from 1000-4000 mg/l. This differs from median background population of MEHP concentrations of about 10 mg/l and less (Wittassek et al., 2007b; CDC, 2009 ). Initially, 5OH-MEHP was higher than 5cx-MEPP by 1000-2000 mg/l; both were in the 5000-10,000 mg/l range. At about 10 h post exposure, both were below 5000 mg/l, and 5cx-MEPP was consistently higher in concentration than 5OH-MEHP, and the highest of all metabolites for the remainder of the 44 h of measurements. All metabolites declined to below 100 mg/l by the end of the 44 h.
Apheresis Platelet Donation Individual
This male individual, aged 35 years having 83 kg body weight, underwent a dual-needle continuous flow platelet apheresis procedure, which involved use of components (tubings, bags, catheters, etc.) containing PVC plasticized with DEHP. Details of the procedure and the measurement of five DEHP metabolites in this individual's urine up to 24 h after exposure are described in Koch et al. (2005a, c) . Concentrations of the four metabolites considered in this article peaked at 4 h after the end of the procedure at 388, 822, 729, and 577 mg/l for MEHP, 5OH-MEHP, 5oxo-MEHP, and 5cx-MEPP, respectively. Note that the concentration of 5cx-MEPP is less than that of 5OH-MEHP for this measurement. After about 8 h, the 5cx-MEPP concentration was the highest of all metabolites, and it remained that way for all remaining urination events. Concentrations of all metabolites were under 200 mg/l after about 12 h and under 65 mg/l after 24 h. On the basis of total mass excreted (i.e., not based on creatinine), Koch et al. (2005c) estimated that the dose of DEHP received by this individual was 2.6 mg, or about 31 mg/kg. It is noteworthy that, like the self-dosed individual, the dose and measured urine concentrations, were higher than typical background exposures several hours after the exposure.
Figures 1 displays the change in this key ratio, the concentration of the tertiary metabolite 5cx-MEPP to the secondary metabolite 5OH-MEHP, over time following cessation of the exposure, for these two individuals. The key trend to note is that this ratio increases throughout most of the experiment. For the self-dosed individual with 2 days of urinations, the ratio continued to rise well into the second day, staying over 2 and once above 3, until the last two events at hours 43 and 44. These last two urination events show a ratio more like 1.5 and could have been the result of the individual's metabolism or some other phenomena. As the DEHP was labeled for this self-dosed individual, the measured metabolites were uniquely identified and the concentrations are known to be the result of the experimental intake. The ratios of the apheresis individual rise continually, with a peak at about 1.85 at the end of the 24-h urine collection period. The benefit of these experiments at high doses is that the trends observed are mostly not influenced by background exposures, and one could surmise that they represent what would happen with any single background dose at a much lower level. This assumes, of course, that the metabolism and disposition of a background intake is reasonably analogous to that of the high self-imposed and apheresis intakes. If a background dose of phthalate occurs as the result of an inhalation exposure, a skinapplied cosmetic or a time-release pharmaceutical, then the trends in urine concentrations might be different compared with an oral dose or a dose directly delivered to the blood stream.
The data from the two highly exposed individuals will be used in the general model developed in this study and used along with the creatinine correction approach to estimate intakes. On the basis of an examination of the ratios, three ''conditions'' after exposure are defined, with the first being shortly after exposure when the ratios are near 1.0, the second reflecting a ratio of about 1.5, which would occur 8-16 h after exposure, and the last, when the ratio is above 2, which might reflect an exposure 24 h or more after exposure. For each condition, a simple ''multiplier'' is developed, which relates the concentration of 5OH-MEHP in urine to the intake dose, as:
where MULT i ¼ multiplier for condition i; DOSE¼ intake dose of DEHP, mg; 48.5 mg for the self-dosed individual, and 2.6 mg for the apheresis patient; C5OH i ¼ representative concentration of 5OH-MEHP in urine during condition i, mg/l. With the units of MULT i in ''l'' (liter), a multiplication of this value by a urine concentration of 5OH-MEHP expressed with a denominator in liters as well (mg/l, mg/l, etc.) will give the single event dose of DEHP in mass consistent with the mass unit of the 5OH-MEHP concentration (mg, mg). This dose can be divided by the individual's body weight to provide a single event dose on a body weight basis, such as mg/kg body weight.
A few caveats in this study are noted before assigning values of the MULT, based on the three conditions and the two individuals. First, this approach importantly assumes that the urine profile of DEHP metabolites resulted from a single exposure in the past, and is not the result of many ongoing intakes. As the MULT values are based on a single dose from the two individuals, this same scenario is assumed in application of the MULT values. This is obviously a critical but not unreasonable assumption. Certainly if dietary exposures are the primary exposures for DEHP, then a dose during a given meal might be the only dose received that day. With elimination half-lives on the order of hours (5-15 h), metabolites from a given exposure are largely excreted within a 24-h period. Certainly, at background ongoing exposures there could be exposures other than those received at a single meal, there could be some delayed metabolism, and other factors that explain a given profile of metabolites. Second, there is no specific reason that the concentration used in Eq.
(1) is that of 5OH-MEHP, although benefits to 5OH-MEHP are that it is typically among the highest concentrations in a profile of DEHP metabolites, it is not the first metabolite formed, and it is consistently quantified. In conclusion, it is assumed that the patterns of metabolism in the highly dosed individuals, and in particular the changing ratios over time, are similar to those experienced in the background population even though individual episodes of exposure in the general population are likely to be much less than in these two conditions.
With that as backdrop, urine events are now selected from the two individuals to develop the values of MULT corresponding to three conditions: condition ''1'': Near the time of exposure, ratio near 1.0; condition ''2'': eight or more hours after exposure, ratio near 1.5; and condition ''3'': 20 h or more after exposure, ratio near or greater than 2.0. These ''near'', ''intermediate'', and ''far in time'' conditions were chosen based on best judgment and an examination of the trends seen in Figure 1 . Table 1 has the selection of these events. Three events are selected from the data on the apheresis patient, the last being the last event measured at 23.5 h, when the ratio of 5cx-MEPP to 5OH-MEHP was 1.85. The self-dosed individual tended to have many more urination events (and lower volume per event) than the apheresis patient F 14 over the first 24 h compared with 6 for the apheresis patient. For this reason, clusters of three events representing each condition were selected to generate the MULT values for this individual. The total mass of each metabolite was summed and divided by the total urine volume over those three events to get the concentrations observed in Table 1 . It is importantly noted that the middle condition, when the ratio of 5cx-MEPP to 5OH-MEHP is about 1.5, comes at a later time for the self-dosed individual as compared with the apheresis individual. This could have been the result of the self-dosed individual's age F he was 61 at the time of the experiment compared with 35 for the apheresis patient. His metabolism may have been slower. The route of exposure F oral for the 61 year old, who self-dosed versus intravenous for the 35-year-old apheresis patient F could also have made a difference in metabolism patterns. In any case, concentrations had declined a lot more (relatively speaking) at hours 13-18 for the self-dosed individual as compared with 7.7 h of the apheresis patient. This resulted in a MULT about a factor of 10 higher in the self-dosed individual for this second condition. The MULT for the other two conditions of interest were similar for both individuals, different only by a factor of 2-3.
Now that the alternate model is set up with these ratios and MULT values, the next step is to apply the model to NHANES data. Measurements of DEHP metabolites in The ''MULT'' is defined as the ratio of the concentration of 5cx-MEPP to 5OH-MEHP.
Critical evaluation of creatinine correction approach Lorber et al. Table 2 . Targeted selections of individual were made based on their potential interest in this analysis: they correspond to the three conditions for which MULT values were developed, and they also span a range of concentrations within each condition. There were six individuals for each of the three conditions for a total of 18 individuals. Half of the individuals within each condition were specifically selected as having concentrations higher than typically found, and the other half had concentrations more like the median concentrations found in NHANES. On the basis of the ratios found, the concentration of 5OH-MEHP is multiplied by the appropriate MULT to estimate the intake dose as per Eq. (1) above. This is compared with a second estimate of an intake dose, derived using the creatinine correction approach. David (2000) and later Wittassek et al. (2007a) provide this generalized equation to calculate intake dose from urinary excretions of the first primary monoester phthalate metabolite:
where DI ¼ the daily intake, mg/kg/day; UE ¼ the phthalate monoester metabolite expressed on a creatinine basis, mg/g creatinine; CE ¼ the daily creatinine excretion normalized to body weight, mg/kg/day; Fue ¼ is the molar fraction of the urinary excreted metabolite in relation to the ingested diester over 24 h after exposure, fraction; 1000 ¼ units conversion factor, mg/g; MWd, m ¼ the molecular weights of the diester phthalate and monoester metabolites, mg/mole. This equation can, in fact, be applied to any of the metabolites, given appropriate assignments of the Fue and MW parameters, and in this study, intake estimates will be derived from all four metabolites for each NHANES individual. Also, the intake will be derived based on the sum of the four metabolites. The Fue parameter, expressed as a fraction, ranged from 0.059 to 0.23, corresponding to the percentages for each metabolite described earlier. For the calculation based on the sum of the concentrations, the Fue is the sum of the fractions, which equals 0.63. The molecular weight of DEHP is 390 mg/mole, and it is 278 for MEHP, 292 for 5oxo-MEHP, 284 for 5OH-MEHP, and 308 for Critical evaluation of creatinine correction approach Lorber et al.
5cx-MEPP. For the application of the model to the sum of the four metabolites, the MW for the metabolite will be assumed to be 290 (average for the four metabolites). Mage et al. (2008) provide these two equations for CE, modeled as mg/day, for male (3a) and female (3b) adults (individuals greater than 18 years of age):
Female CE ¼ 0:993Â1:64Â 140 À age year
where B ¼ 1 if the individual is black and 0 if not. In the retrieved NHANES data set, seven individuals are described as ''non-Hispanic white'' (B ¼ 0), four individuals are described as ''non-Hispanic black'' (B ¼ 1), six are described as Mexican American (B ¼ 0), and one is described as, other hispanic (B ¼ 0), ht, height; wt, weight.
Results and discussion
Before describing the results of this exercise, it is noted that the Supplementary Material to this article contains additional analyses that are pertinent to the discussion, and that will be referenced. These include an evaluation of the key metabolite ratios that were found in an experiment involving three individuals who fasted for 2 days (glass-bottled water only), and application of the creatinine correction approach to the two highly exposed individuals.
The results of this analysis are provided in Table 3 , which shows the intake of DEHP calculated for each individual from NHANES as estimated using both methods. The creatinine correction approach is applied to all four metabolites and the total concentration, and the MULT method is applied to each individual using both values of MULT. Several trends are apparent from this table, and they are provided here in list form:
(1) The most important result, for purposes of the analysis in this article, is that the predictions for condition 3, when the ratio of the secondary metabolites suggest an intake that occurred in the most distant past (24 h or more), are significantly different between the creatinine correction approach and the MULT approach. The MULT approach leads to intakes that are between about 10 and 50 times higher than the creatinine correction approach for five of the six individuals; it is only higher by factors near and less than five for the other individual. In contrast, the predictions are about the same between the creatinine correction and the MULT approach for condition 1 F when the ratio of the secondary metabolites suggests an exposure in the more recent past. In fact, the MULT predictions based on the apheresis 1a  18  221  133  189  189  137  282  1b  23  18  18  19  19  17  35  1c  80  125  168  140  136  94  193  1d  1  2  2  2  2  1  2  1e  1  2  2  2  2  1  1  1f  1  3  2  3  3  1  2  2a  21  23  21  44  29  36  392  2b  29  87  99  169  110  228  2491  2c  27  64  53  122  76  107  1166  2d  2  2  2  4  3  5  52  2e  1  4  5  8  5  3  34  2f  o1  1  1  1  1  1  1 0  3a  5  4  5  12  7  75  202  3b  6  16  13  53  26  256  690  3c  58  64  70  216  110  365  981  3d  2  3  2  11  5  45  120  3e  1  1  2  6  3  37  100  3f  o1  1  1  2  1  1 1  2 Critical evaluation of creatinine correction approach Lorber et al.
patient for condition 1 are mostly lower than the creatinine correction approach.
(2) For condition 2, when the ratio of the secondary metabolites suggests an exposure 8-16 h range in the recent past, the results are different depending on the MULT used. They are comparable when the MULT was determined based on the apheresis patient and took on a value of about 8, but are much higher for the MULT approach when the value of the MULT was about 90 based on the self-dosed individual's data. (3) Looking just at the creatinine correction predictions, several important observations are made, which include: (a) They are similar among the four metabolites in five of six cases examined under condition 1, when the exposure is ''near'' the measurement. It is observed from Table 2 that the concentration of MEHP is about a factor of three to five lower than the other three metabolites in five of the six individuals in condition 1. As well, the concentrations of the other three metabolites are within about a factor of two of each other. These relationships are consistent with the relationships between the fractions of each metabolite eliminated after 24 hours from a given dose of DEHP discussed earlier (which are also the ''Fue'' fraction parameter used in the creatinine correction approach, Eq. (2)). The individual identified as ''1a'' had a unique trend in this group in that the concentration of MEHP, whereas high at 63 mg/l, is still well over an order of magnitude lower than the other metabolites, which had concentrations in the thousands of mg/l. In this case, the prediction based on MEHP was appropriately lower by about an order of magnitude compared with the other metabolites. (b) In conditions 2 and 3, predictions of DEHP intake based on MEHP are now the lowest and 5cx-MEPP predictions now the highest. As can be observed from Table 2 , MEHP concentrations are following further behind that of the other three metabolites in condition 2 compared with condition 1, and 5cx-MEPP is getting further ahead of the other metabolites. The creatinine-based predictions track these trends. In condition 3, 5cx-MEPP is now even further from the other three metabolites as compared with the other categories, and this is reflected in a similar discrepancy in creatinine-based predictions F those based on 5cx-MEPP are 3-5 times higher than those based on MEHP, 5OH-MEHP, or 5oxo-MEHP. (c) Predictions based on the total concentration, all fall within the middle of the predictions bracketed by the lowest predictions based on MEHP and the highest predictions based on 5cx-MEPP. This might argue for the consistent use of a total concentration when using the creatinine correction approach for estimating intakes. It might compensate for any misleading predictions based on subtleties that could occur at the extremes shown by MEHP and 5cx-MEPP.
(4) All of the trends noted above are the same whether concentrations taken from NHANES 2003/2004 are high or more typical. Whereas creatinine-based predictions appears close together for the low concentrations, there were actually similar proportional differences as were noted aboveFthese are masked when rounding to the nearest whole number for the table. Most importantly, the patterns when using the MULT approach are the same whether the NHANES concentrations are high or typical. Specifically, there is a factor of 10 or more difference between the MULT predictions and the creatinine predictions in condition 3, regardless of whether the NHANES concentrations are high or low.
All of these trends in both concentrations and intakes are consistent with the premise that the urine concentrations from NHANES 2003/2004 are driven by the most recent exposure, and that this most recent exposure could have occurred very ''near'' the time of sampling (''condition 1'' F a few hours earlier) or could even have occurred ''distant'' from the time of sampling (''condition 3'' F 24 h or more before the urine sample was taken). In addition, this most recent exposure could have been large in magnitude or small. As discussed earlier, the profile of metabolites in the urine will change over time from a given intake of DEHP, assuming no further exposures occur. All metabolites will decline in concentration, but MEHP will decline the fastest because it has a short elimination half-life of 5 h, and eventually 5cx-MEPP will dominate the profile as it has the longest half-life of all metabolites at 15 h. If the most recent intake of DEHP occurred 24 h or more before the urine sample than the measurements of metabolites in the urine might not be good indicators of daily exposure. Certainly, for MEHP, five halflives have occurred by the urine sampling time, and the concentration is subsequently very low in comparison to what it might have been had urine samples been taken near the time of exposure. In this case, using MEHP to calculate daily intake of DEHP might result in a significant underprediction of the actual DEHP exposure from the previous day.
The Supplementary Material includes an evaluation of the creatinine correction approach applied to the two highly dosed individuals (as creatinine was also measured in the urine along with the DEHP metabolites). It is shown that initially for about 8 h after exposure, the creatinine correction approach would overestimate the known intake, but after that intakes are underestimated, by up to a factor of 10 after 24 h and up to a factor of 100 after 40 h. The initial overestimation is not unexpected as the creatinine correction approach implicitly assumes that every urination event represents an average for the day, but with first order elimination kinetics, the initial mass excreted will be higher than an average with subsequent excretions much lower than an average. By the second day after the elevated exposure, only small amounts are excreted by the two individuals and consequently, the creatinine correction approach predicts small intakes.
One can now begin to formulate hypotheses about proper interpretation of NHANES results using the creatinine correction approach. If a urine sample is taken after an exposure to DEHP, on the same day of that exposure, there may be some overprediction and some underprediction, such that the creatinine correction approach on average might give a reasonable approximation of exposure. The same might be true if the exposure was during the previous night and the sample was taken next morning. However, if the sample was taken perhaps 24 h or more after the exposure, the underprediction might be by a factor of 10 or more. As an example, say an exposure of 10 units occurred on day 1 and the measurement was taken that same day after the exposure. The creatinine correction might be predicting anywhere from, say, 3-20 units. However, if the measurement is taken more than 24 h later with no further exposures to DEHP, the creatinine correction approach might suggest an exposure of 1 unit. If taken 2 days later, the creatinine correction might suggest an exposure of 0.1 unit.
An underprediction of intakes might be frequent and a strong deterrent to the regular use of the creatinine correction approach for DEHP. To gain further insight as to what NHANES is saying with regard to DEHP exposure, in the context of the evaluation in this study, the NHANES 2003/ 2004 database, including measurements of the four DEHP metabolites, was rank ordered in two ways: (1) one rank ordering was based on the concentration of MEHP, from lowest to highest MEHP, and (2) the second rank order was based on the ratio examined in this article, the ratio of the concentrations of 5cx-MEPP to 5OH-MEHP, from lowest to highest ratio. For each rank ordering, the key ratio was examined as well as the average concentrations of the four metabolites. Results of this rank ordering are shown in Table 4 . Looking at the rank ordering based on MEHP concentrations (the first half of the table), it is observed that the first quartile is composed entirely of nondetects for MEHP. The average concentration for the second quartile is 1.3 mg/l. The maximum of that quartile, or the median concentration in the dataset (however, not the populationweighted median), is 2.2 mg/l. The averages of the key ratio for these two quartiles were 1.7 and 2.4. The nondetects and low MEHP concentrations of these two lower quartiles, in combination with high ratios, suggests that this half of the NHANES data set is comprised of individuals whose exposures to DEHP could be in the (relatively) distant past, perhaps more than 8 h and even more than 24 h. As discussed above, the creatinine correction may be underestimating intakes if the exposure was 8 h or more in the past. The concentrations increased for the other half of the NHANES data set, with average quartile MEHP concentrations of 3.7 and 25.7 mg/l. The ratios for the second two quartiles declined to 1.6 and 1.4. Thus, for this half of NHANES, the weight-of-evidence suggests that exposures were more recent and the creatinine correction might give more appropriate estimates, or even overestimates, of these exposures. A similar overall finding is noted when examining the second half of the table, which shows the rank ordering based on the key ratio. When it is low, as in the first quartile that has an average ratio of 1.0, the MEHP concentration is high: 13.3 mg/l. MEHP concentration declines as the key ratio increases.
Conclusions
The findings in this study hinge on the key assumption that profile of DEHP metabolites in urine reflects only the most recent exposure, even if that exposure was 24 h or more in the past. The issue is just that: can a ratio of 2 (or thereabouts) between the tertiary and secondary metabolites be explained by an exposure scenario other than the most recent exposure Critical evaluation of creatinine correction approach Lorber et al.
being 24 h earlier (or thereabouts; barring measurement error, of course)? Whether the answer to this question is an unambiguous ''yes'', then the analysis in this article might be questioned, because the alternate model is based on single high exposures to two individuals and the ratios that resulted from these exposures over time. At the very least, the analysis in this article represents a limiting case F that the exposures to these individuals are indeed representative of one possible exposure scenario which members in the general population (e.g., as represented in NHANES) are also experiencing. Actually, one can probably go further than that. If the elimination of DEHP metabolites does follow first-order kinetics with overall elimination of half-lives of the key metabolites on the order of 10-15 h, progressing from generation of primary, secondary, and then tertiary metabolites, then a qualitative (or a quantitative given time) argument can be made that a ratio of 2 can occur only many hours after a single bolus exposure. Otherwise, no other scenario could result in this high a ratio, as subsequent and even smaller exposures would produce new mass of metabolites, added to the reservoir of metabolites from the earlier dose, such that a high ratio between 5cx-MEPP and 5OH-MEHP would not occur in urine. It stands to reason that ratios near 1.0 (in the context of the analysis in this article) can only be explained by one or more exposures near the time of urine measurement in the same way that high ratios greater than 2 can only be explained by single distant exposures.
However, this remains the key uncertainty of this analysis. Other uncertainties exist as well. The alternate model is based on exposures of two individuals that were elevated over background. As elevated exposures, there could be patterns of metabolism that might not be observed in the general population mostly experiencing lower exposures. Insight as to this possibility is gained from a discussion of data in the Supplementary Materials. That analysis shows the key ratio of this study in urine samples of three individuals after they ceased eating, and for 2 days afterwards. The general trend is that, like the two individuals experiencing high exposures, the ratio is initially near 1.0, but with time, it rises to over 2.0, then dips, and then rises again. Overall, the concentrations decline from the first urination event to levels one-tenth as high by 24 h and throughout the rest of the fast. These trends support the hypothesis that food was the primary source of DEHP exposure to these individuals, and that over time, the tertiary DEHP metabolite, 5cx-MEPP, will dominate the profile. However, the rise in the ratio followed by the decline and then another rise, suggest a mechanism of delayed metabolism or release of metabolites from body storages.
Other factors that that could affect metabolism include age, sex, race, method of exposure (oral, dermal, intravenous, and inhalation), and other factors. More longitudinal data on individuals with known exposures is needed, but this data could not be found in the literature.
NHANES presents results in terms of percentiles, and the 50th percentile, or the median, is often portrayed as the best indicator of a central tendency of exposure. However, is it really the best indicator? Further considering the hypothetical scenario portrayed earlier, in which the creatinine correction approach might correctly suggest an intake of 10 units on the day when the 10 units exposure occurred, but then 1.0 and 0.1 unit exposure occurred for the next 2 days. If this individual's urine is sampled on these three days, the median exposure would be estimated as 1.0 units. Is this the best indicator of the central tendency for this individual? Taking it further, say an entire population is exposed once every 3 days to ''10'' units of DEHP, and a random survey takes 1/3 of all samples on the day of exposure, 1/3 the day after exposure, and 1/3 2 days after exposure. The ''actual'' mean exposure is 3.3 units, and if the creatinine correction were applied to every measurement, one would calculate a mean exposure of 3.7 units. Maybe a better indicator of a central tendency of exposure to DEHP and other phthalates could be obtained by using the creatinine correction method on all samples and then taking the mean, instead of relying on a median.
From a public health perspective, maybe the most important concern raised in this analysis is the proper identification and interpretation of those most exposed to DEHP. CDC (2009) lists the 95th percentile concentration of MEHP as 31.0 mg/l as though this concentration represented the 95th percentile in exposure. But maybe all it represents is a concentration that would result from an exposure (lunch perhaps) that occurred a few hours before the sample was taken. Maybe the highest exposures are those where MEHP is nondetected in the sample, as discussed earlier. Looking again at the order of the rank based on the key ratio between 5cx-MEPP and 5OH-MEHP, the 95th-100th percentile individuals had ratios from 3.3 to 20.0 (130 of 2605 individuals). MEHP was nondetected (DL ¼ 0.6) in 75% of these samples. Would the creatinine correction equation applied to these individuals have underpredicted DEHP intakes by up to 2 orders of magnitude?
Although there are uncertainties with the analysis in this article, it nonetheless suggests that the creatinine correction approach be applied cautiously for contaminants, which share these key similarities to phthalates: (1) whereas exposure is widespread in a population (even 100% of individuals showing evidence of exposure through urine measurements), the exact pattern of exposure is still uncertain. It is not known whether exposures occur once per day, multiple times within a day, or only sporadically (every few days or more), and (2) the elimination half-lives of the metabolites are on the order of hours such that elimination is substantially complete by 24 h.
Although pointing out these issues, this study cannot, however, suggest a viable alternative to the creatinine correction approach at this time. With more experimental data and study on the human metabolism of phthalates, a simple model, such as the one developed from the two individuals, could provide a more valid indication of the timing and magnitude of recent DEHP exposures. Concurrently, it is recommended that further study on exposure should focus on the pathways of exposure and the concentrations found in important exposure matrices, including food, air, dust, water, cosmetics, medications, and other exposure media.
